Chinese NMPA Accepts New Drug Application for Illuccix
Filed with ASX · · 3 pages · English
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings CallMelbourne (Australia) and Indianapolis, IN (U.S.) – 20 January 2026. Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has accepted the filing of a New Drug Application (NDA) for TLX591-Px (Illuccix®, Kit for the preparation of 68Ga-PSMA-11), Telix’s lead prostate cancer i
Telix Pharmaceuticals Limited on 6ix
Story so far
Earlier from Telix Pharmaceuticals
- First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
- Telix to Present Pipeline and Commercial Portfolio Overview at J.P. Morgan Healthcare Conference
- Precision Medicine Portfolio Update
- ProstACT Global Study Status
- Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration
Later from Telix Pharmaceuticals
- Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch
- Telix Achieves FY25 Guidance - US$804M, Q4 Growth
- First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients
- Telix Full Year Results 2025 Investor Webcast Notification
- Telix Submits EU MAA for TLX101-Px Brain Cancer Imaging
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals